PURPLE BIOTECH LTD.
PPBTNasdaq
$1.47
0.0%Jul 17 close · end-of-day
Price
1Y↓ -94.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
—
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
—
Net Cash
—
Return 1Y
-94.2%
Company profile
Purple Biotech Ltd. focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors. NT219, a small molecule that targets insulin receptor substrate substrate substrate 1 and 2, and signal transducer and activator of transcription, is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors.
- CEO
- Gil Efron
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Website
- purple-biotech.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2020 | FY2021 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | — | — |
| Net income | — | — |
| Diluted EPS | — | — |
| Operating cash flow | — | — |
| Free cash flow | — | — |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
No quarterly data.
Company news
Jun 11, 2026
- 39d agoPurple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT)investorshub.advfn.com
- 39d agoPurple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Windowfinance.yahoo.com
May 15, 2026
Apr 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.